Apoptosis Intervention in Cell and Organ Preservation

描述（由申请人提供）：BioLife Solutions Inc.纳入 1998年3月，专门为 人体细胞、组织和器官的低温和冷冻保存。的 公司的研究人员部分由分子生物学家组成， 积累的证据支持的概念，最好的方式， 制定未来的保存方案是了解细胞的分子 在保存储存制度期间引发的死亡级联。BioLife 开发了HypolhermosolR（HTS）系列的低温和 基于这种分子生物学设计的冷冻保存溶液 策略，并为细胞特异性应用而独特地配制。BioLife的 本文所述的第一阶段工作的成功完成， 将HTS销售给多个企业、学术和政府团体。BioLife拥有 被选中与Vitagen公司和迈阿密糖尿病大学合作 研究所（DRI）开发两种特殊的HTS配方， Vitagen的体外肝脏辅助装置（HTS-ELAD）的运输/储存，以及 DRI的可移植胰岛（HTS-ISLETS）。BioLife提出三个 研究主题在这第二阶段SBIR。首先，BioLife将继续其基本的 诱导细胞凋亡的分子机制研究 死亡这一基础研究举措在保存行业是独一无二的 并为DRI采用HTS进行人类胰岛移植做出了贡献。 第二，BioLife将用凋亡和坏死抑制剂修改HTS 通过文献鉴定以及合成的维生素E类似物 通过组合化学，使HTS-ELAD和HTS-ISLETS可以 优化最后，第二阶段项目最具挑战性的主题是 开发蛋白质芯片高通量检测系统， BioLife第三阶段添加剂发现计划的基石。反过来，这将 使公司能够利用微阵列进行快速分析， 技术，以便未来可以开发更多的I-ITS变体 客户. 拟定商业应用： 不可用

DESCRIPTION (provided by applicant): BioLife Solutions Inc. was incorporated in March, 1998, and specializes in developing solutions and procedures for the hypothermic and cryopreservation of human cells, tissues and organs. The Company's research staff is composed, in part, of molecular biologists who have accumulated evidence supportive of the concept that the best manner in which to formulate future preservation solutions is to understand the molecular cell death cascades that are triggered during preservation storage regimes. BioLife has developed the HypolhermosolR (HTS) family of hypothermic and cryopreservative solutions that is designed based on this molecular biology strategy and is uniquely formulated for cell-specific applications. BioLife's successful completion of the Phase I work described herein has resulted in the sale of HTS to several corporate, academic, and government groups. BioLife has selected to work with Vitagen Corporation and the University of Miami Diabetes Research Institute (DRI) to develop two special HTS formulations for the shipping/storing of Vitagen's Extracorporeal Liver Assist Device (HTS-ELAD) and DRI's transplantable pancreatic islets (HTS-ISLETS). BioLife proposes three research themes in this Phase II SBIR. First, BioLife will continue its basic research on the molecular mechanisms underlying preservation-induced cell death. This basic research initiative is unique in the preservation industry and contributed to DRI's adoption of HTS for human islet transplantation. Second, BioLife will modify HTS with apoptotic and necrotic inhibitors identified through the literature as well as Vitamin E analogues synthesized through combinatorial chemistry so that HTS-ELAD and HTS-ISLETS can be optimized. Finally, the most challenging theme of the Phase II project is to develop a ProteinChip microarray high throughput assay system that will be the keystone of BioLife's Phase III additive discovery program. This, in turn, will allow the company to perform rapid assays by harnessing the microarrav technology so that additional I-ITS variants can be developed for future clients. PROPOSED COMMERCIAL APPLICATION: Not Available